# Neuroprotection of Memantine and Rosuvastatin

Source: https://onco.cc/trials/nct07504198/  
OnCo record `nct07504198` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of memantine in colorectal cancer, run by Tanta University, not yet recruiting.

## Summary

Neuroprotection of Memantine and Rosuvastatin is a phase 2/3, randomised interventional study registered as NCT07504198 by Tanta University, with a registry enrolment figure of 46 participants, started 2026-03 and due to reach its primary completion in 2027-04. Interventions recorded: Starch Placebo; Memantine; Rosuvastatin 20 Mg Oral Tablet. Conditions listed: Peripheral Nerve Disease. Primary outcome: The primary outcome is the percentage of patients with sensory neuropathy grade ≥ 2 according to National Cancer Institute Common Terminology Criteria for Adverse Events for grading of neuropathy from 1 to 5 based on severity.. Colorectal eligibility wording from the registry: "* Patients with histologically confirmed diagnosis of stage III or stage IV colorectal cancer". Sites: Egypt. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07504198
- Phase: 2/3
- Setting: Neuroprotective Effect of Memantine and Rosuvastatin Against Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer
- Sponsor: Tanta University
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT07504198: https://clinicaltrials.gov/study/NCT07504198

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- drugs: [Memantine](https://onco.cc/drugs/memantine/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07504198.json